U.S. markets open in 41 minutes
  • S&P Futures

    3,224.50
    -13.50 (-0.42%)
     
  • Dow Futures

    26,568.00
    -147.00 (-0.55%)
     
  • Nasdaq Futures

    10,889.50
    -2.25 (-0.02%)
     
  • Russell 2000 Futures

    1,438.10
    -8.90 (-0.62%)
     
  • Crude Oil

    40.01
    -0.30 (-0.74%)
     
  • Gold

    1,859.40
    -17.50 (-0.93%)
     
  • Silver

    22.79
    -0.41 (-1.75%)
     
  • EUR/USD

    1.1644
    -0.0031 (-0.27%)
     
  • 10-Yr Bond

    0.6540
    -0.0120 (-1.80%)
     
  • Vix

    29.43
    +0.85 (+2.97%)
     
  • GBP/USD

    1.2743
    -0.0009 (-0.07%)
     
  • USD/JPY

    105.4690
    +0.0670 (+0.06%)
     
  • BTC-USD

    10,625.89
    -134.70 (-1.25%)
     
  • CMC Crypto 200

    226.16
    +17.22 (+8.24%)
     
  • FTSE 100

    5,796.92
    -25.86 (-0.44%)
     
  • Nikkei 225

    23,204.62
    +116.80 (+0.51%)
     

Cortexyme to Participate in Virtual Fireside Chat Hosted by LifeSci Capital on July 30, 2020

-- Presentation to be webcast on Cortexyme’s website

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Stephen Dominy, M.D., the company’s chief scientific officer and co-founder, will participate in a fireside chat hosted by LifeSci Capital on Thursday, July 30 at 3:00 p.m. EDT / 12:00 p.m. PDT. The conversation will focus on the link between P. gingivalis and Alzheimer’s disease pathology.

A live webcast of the fireside chat will be accessible at the Investor Calendar page under the News & Events heading of the Cortexyme investor site (ir.cortexyme.com). The webcast will be archived at that location for 14 days.

About Cortexyme, Inc.

Cortexyme (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer’s disease. Cortexyme is targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients and tied to neurodegeneration and neuroinflammation in animal models. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

Forward-Looking Statements

Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words. Examples of forward-looking statements include, among others, statements we make regarding our business plans and prospects, the timing and success of our clinical trials and related data, the potential of atuzaginstat to treat Alzheimer’s disease , our ability to fund planned operating and capital expenditures, the timing of announcements and updates relating to our clinical trials and related data, the timing of and our ability to enroll patients into our clinical trials, and the potential therapeutic benefits, safety and efficacy of our product candidate or library of compounds. Forward-looking statements are based on Cortexyme’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 16, 2020, our Quarterly Report on Form 10-Q filed with the SEC on May 12, 2020, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Cortexyme undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200729005502/en/

Contacts

Media Contact:
Hal Mackins
For Cortexyme, Inc.
hal@torchcomllc.com
(415) 994-0040

Investor Contact:
Chris Lowe
Chief Financial Officer
Cortexyme, Inc.
clowe@cortexyme.com